

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12N 15/62, 15/83, C07K 14/08, 14/435, C12N 7/01, 5/10</b>		<b>A1</b>	(11) International Publication Number: <b>WO 96/12027</b>
			(43) International Publication Date: 25 April 1996 (25.04.96)
(21) International Application Number: <b>PCT/GB95/02457</b>			(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).
(22) International Filing Date: 18 October 1995 (18.10.95)			
(30) Priority Data: 9420989.7 18 October 1994 (18.10.94) GB 9511729.7 9 June 1995 (09.06.95) GB			
(71) Applicant (for all designated States except US): SCOTTISH CROP RESEARCH INSTITUTE [GB/GB]; Invergowrie, Dundee DD2 5DA (GB).			
(72) Inventors; and (75) Inventors/Applicants (for US only): CHAPMAN, Sean, Nicholas [GB/GB]; 190 Lochee Road, Dundee DD2 2NF (GB). SANTA CRUZ, Simon, Peter [GB/GB]; Tayview, 29 Hazel Avenue, Dundee DD2 1QD (GB). OPARKA, Karl, John [GB/GB]; 2 Pipers Way, Auchterhouse, Dundee DD3 0QS (GB). WILSON, Thomas, Michael, Aubrey [GB/GB]; The Coach House, 4 Balruddery Meadows, Invergowrie DD2 5LJ (GB).			
(74) Agent: MURGITROYD & COMPANY; 373 Scotland Street, Glasgow G5 8QA (GB).			<b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: METHOD OF PRODUCING A CHIMERIC PROTEIN			
(57) Abstract <p>A method of producing a chimeric protein from i.e. a plant virus coding for such a protein. The method allows the production of large (i.e. 25 kDa) proteins which assemble with the virus in infected host cells and are arranged on the outer surface of chimeric viruses. A vector for the production of biologically useful proteins in such a manner is also disclosed.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				



1     METHOD OF PRODUCING A CHIMERIC PROTEIN

2

3     This invention relates to a method of producing a  
4     chimeric protein, eg a biologically active protein such  
5     as an antibiotic peptide.

6

7     Typical antibiotic peptides include the marginins, 23  
8     amino acid-long alpha-helical peptides, originally  
9     identified from frog skin, which have significant  
10    antibacterial activity; the defensins which combat  
11    bacteria, fungi and some enveloped viruses such as  
12    herpes simplex virus and HIV; and the protegrins which  
13    are 16-18 amino acid-long antibiotic peptides with  
14    strong biocidal activity.

15

16    The protegrins form part of an array of antibiotic  
17    peptides that are used by mammalian phagocytes to  
18    destroy invading pathogens through non-oxidative  
19    processes. Typically the protegrins include 4 cysteine  
20    residues and form a double-stranded  $\beta$ -sheet structure  
21    and show sequence similarity with the antibiotic  
22    defensin peptides that are also involved in phagocyte  
23    defence responses. The defensins are cationic,  
24    cysteine-rich peptides of 29 to 34 amino acids that are  
25    formed almost entirely of  $\beta$ -sheet structures and that

1 have been shown to have biocidal activity against  
2 bacteria, fungi and some enveloped viruses, including  
3 herpes simple virus and HIV. Both the protegrins and  
4 defensins are expressed in phagocytes as pre-pro-  
5 proteins which are cleaved to release the biocidal  
6 peptides from the carboxy-terminus of the protein.

7  
8 Because of their antibacterial activity it may not be  
9 convenient to synthesize these antibiotic peptides by  
10 genetic engineering in conventional prokaryotic  
11 expression systems. Solution synthesis of large  
12 amounts of these peptides with a variety of amino acid  
13 modifications may be possible, but is not currently  
14 considered commercially viable, since a significant  
15 drop in yield occurs in the manufacture of peptides of  
16 over 25-30 amino acid residues.

17  
18 Eukaryotic expression systems (yeast, insect, animal or  
19 plant cells which produce foreign proteins or peptides)  
20 may be necessary if there is a need for post-  
21 translational modification of the desired protein, but  
22 fermentation processes for such eukaryotic expression  
23 systems are expensive to maintain, provide little  
24 flexibility in terms of scaling the process up to  
25 industrial production levels and are very susceptible  
26 to contamination. Processing and purification of the  
27 desired protein can also be complex and costly.

28  
29 The use of plants and benign plant viruses offers an  
30 opportunity to produce foreign proteins with minimal  
31 host cell contamination, thereby reducing contamination  
32 problems which could affect successful achievement of  
33 the required regulatory body approval for human or  
34 veterinary applications.

35  
36 It has been proposed in WO92/18618 to use plant viruses

1 as vector systems for the expression of foreign  
2 nucleotide sequences. WO92/18618 describes the use of  
3 a Comovirus (Cowpea Mosaic Virus or CPMV) as an  
4 effective vector for such expression and also mentions  
5 other spheroidal viruses such as HIV and Picorna-  
6 viruses. Picornaviridae generally comprise particles  
7 of 22-30nm having cubic symmetry; Comoviridae have a  
8 pair of 28nm particles with a similar symmetry, and HIV  
9 is a member of the Retroviridae which are generally  
10 enveloped 100nm particles containing an icosahedral  
11 nucleocapsid.

12  
13 One disadvantage of the system disclosed in WO92/18618  
14 is that the geometry of the spheroidal viruses  
15 precludes large proteins from being produced, since the  
16 size and number of chimeric proteins per virus particle  
17 (generally 60 for icosahedral virus particles) is  
18 limited by the spheroidal geometry of the virus.

19  
20 Construction of chimeric proteins in such viruses is  
21 also limited to the insertion of the foreign component  
22 into a loop in a native virus protein, eg the  $\beta$ -B to  $\beta$ -  
23 C loop in VP23 of CPMV, where such insertion does not  
24 affect the geometry of the coat protein and/or its  
25 ability to self-assemble into a virus particle  
26 (virion). As can be appreciated, the size of the  
27 peptide which can be tolerated in such an insertion is  
28 fairly limited; polypeptides of a maximum of 26 amino  
29 acids in length are cited by WO92/18618. Larger  
30 polypeptides present in internal insertion sites in  
31 coat or capsid proteins of the viruses exemplified may  
32 result in disruption of the geometry of the protein  
33 and/or its ability to successfully interact with other  
34 coat proteins leading to failure of the chimeric virus  
35 to assemble. Modified viruses which cannot self-  
36 assemble might not infect other host cells and produce

1 whole plant infection. This possible lack of ability  
2 to spread the infection of the modified virus  
3 constitutes a significant disadvantage in the prior  
4 system.

5  
6 The present invention contemplates the use of benign  
7 high copy number rod-shaped viruses, preferably plant  
8 viruses such as potato virus X (PVX), to produce  
9 foreign protein connected to viral coat protein  
10 subunits. When assembled, the virus particles comprise  
11 long helical arrays of more than 1000 identical  
12 chimeric proteins (which are typically coat protein -  
13 foreign protein fusion molecules) per virion.  
14 Generally the foreign protein portion will be displayed  
15 on the outer surface of the virus particles.

16  
17 A suitable proteolytic degradation site (eg elastase or  
18 CNBr) may be engineered into the chimeric protein to  
19 permit release of the foreign protein portion from  
20 purified virus material. Given the size of the foreign  
21 protein and the relevant composition of the possible  
22 viruses, it is estimated that between 10 and 30% of the  
23 total weight yield of virus particle could comprise the  
24 foreign protein. Release of the foreign protein by  
25 proteolytic cleavage can be a simple purification  
26 regime, followed by removal of the residual innocuous  
27 plant virus itself. Yields of plant virus up to 5g per  
28 kg wet weight of leaf from potato or tobacco are  
29 possible and hence the yields of foreign protein could  
30 be very substantial.

31  
32 If the foreign protein is left attached to the chimeric  
33 protein in the virus particle, the whole virus particle  
34 can also be used as a vector for expression and  
35 presentation of peptide epitopes for vaccination of  
36 animals and/or the delivery of therapeutic single-

1     stranded RNA molecules. This may be of utility in the  
2     delivery of anti-sense or triplex nucleotides.

3

4     The present invention provides a method of producing a  
5     chimeric protein comprising:

6

7         a. providing a rod-shaped recombinant virus or  
8             pseudovirus containing a polynucleotide encoding a  
9             chimeric protein having a first (viral) portion  
10            and a second (non-viral) portion, the chimeric  
11            protein being capable of assembly into a virus  
12            particle such that the second portion is disposed  
13            on the exterior surface of the assembled virus  
14            particle;

15

16         b. infecting a host cell with the virus or  
17             pseudovirus; and

18

19         c. allowing replication of the virus or pseudovirus  
20             and expression of the chimeric protein in the host  
21             cell.

22

23     The term "rod-shaped" as applied herein to viruses  
24     includes filamentous or flexuous viruses, which are  
25     preferred. It is advantageous to use a virus which is  
26     flexuous (ie which can bend easily) since chimeric  
27     proteins with large second portions may be able to  
28     assemble more easily into virus particles (virions)  
29     which are flexuous than those which are rigid. PVX is  
30     preferred since it forms a flexuous virion.

31

32     The virus or pseudovirus can preferably assemble in the  
33     host cell to produce infective virus particles which  
34     comprise nucleic acid and chimeric protein. This  
35     enables the infection of adjacent cells by the  
36     infective virus or pseudovirus particle and expression

1 of the chimeric protein therein.

2

3 The host cell can be infected initially with virus or  
4 pseudovirus in particle form (ie in assembled rods  
5 comprising nucleic acid and protein) or alternatively  
6 in nucleic acid form (ie RNA such as viral RNA; cDNA or  
7 run-off transcripts prepared from cDNA) provided that  
8 the virus nucleic acid used for initial infection can  
9 replicate and cause production of whole virus particles  
10 having the chimeric protein.

11

12 The term "pseudovirus" as used herein means a virus-  
13 derived nucleic acid sequence optionally assembled into  
14 particles and having an incomplete viral genome as  
15 compared to wild-type virus but retaining sufficient  
16 viral genes to allow replication and assembly of the  
17 pseudovirus. The virus or pseudovirus may contain  
18 genetic material foreign to the wild-type virus.

19

20 Optionally, the virus or pseudovirus can be purified  
21 from the host cell in order to concentrate the chimeric  
22 protein, ie by polyethylene glycol precipitation and/or  
23 density gradient centrifugation.

24

25 Optionally, the method may include the step of  
26 separating a protein derived from the second portion  
27 from the remainder of the chimeric protein after the  
28 virus or pseudovirus has been purified from the host  
29 cell.

30

31 A linker peptide can be incorporated between the first  
32 and second portions and may have the function of  
33 spacing the two portions from one another, reducing  
34 steric restrictions. Optionally the linker peptide  
35 may contain a proteolytic or chemical cleavage site.

36



1 The term "proteolytic or chemical cleavage site" refers  
2 to a short sequence of amino acids which is  
3 recognisable and subsequently cleavable by a  
4 proteolytic enzyme or chemical means. Suitable  
5 proteolytic enzymes include trypsin, pepsin, elastase  
6 and the like. Alternatively the proteolytic or  
7 chemical cleavage site may be a site which is  
8 vulnerable to cleavage by other means, for example by  
9 addition of chemicals such as cyanogen bromide (CNBr)  
10 or acids or by shear. Preferably, the proteolytic or  
11 chemical cleavage site is an elastase cleavage site,  
12 but other suitable proteolytic cleavage sites can be  
13 used with corresponding enzymes.

14

15 The protein derived from the second portion may be  
16 separated from the remainder of the chimeric protein  
17 before assembly of the virus particle, eg during  
18 expression of the genetic material coding for the  
19 chimeric protein, or during assembly of the chimeric  
20 protein into a virus particle. In this embodiment the  
21 host cell will contain free protein derived from the  
22 second portion. This embodiment can be useful when  
23 expression of very large proteins derived from the  
24 second portion is desired. In such an embodiment, the  
25 proteolytic or chemical cleavage site may be selected  
26 to cleave automatically in a virally-infected host  
27 cell.

28

29 The term "proteolytic or chemical cleavage site" may  
30 thus also include sequences that cleave automatically  
31 such as the FMDV (Foot and Mouth Disease Virus) 2A  
32 protease.

33

34 The proteolytic or chemical cleavage site may be an  
35 integral part of either the first or second portion.  
36 Hence either/or both of the portions may include an

1 integral proteolytic or chemical cleavage site.

2

3 Thus the present invention also provides a method of  
4 producing a chimeric protein as defined above, wherein  
5 the protein derived from the second portion is purified  
6 directly from the host cell after expression.

7

8 The second portion and/or the protein derived therefrom  
9 may be relatively large eg over 10kDa. Proteins of 25-  
10 30 kDa are suitable for production by the method and  
11 even proteins up to 60-70 kDa have been shown to be  
12 produced by the method of the invention.

13

14 The first (viral) portion of the chimeric protein may  
15 be any protein, polypeptide or parts thereof, derived  
16 from a viral source including any genetically modified  
17 versions thereof (such as deletions, insertions, amino  
18 acid replacements and the like). In certain  
19 embodiments the first portion will be derived from a  
20 viral coat protein (or a genetically modified version  
21 thereof). Mention may be made of the coat protein of  
22 Potato Virus X as being suitable for this purpose.  
23 Preferably the first portion has the ability to  
24 aggregate into particles by first-portion/first portion  
25 association. Thus, a chimeric protein molecule can  
26 assemble with other chimeric protein molecules or with  
27 wild-type coat protein into a chimeric virion.

28

29 In a preferred embodiment of the invention the particle  
30 is derived from a potyvirus or even more preferably a  
31 potexvirus such as PVX, and in such an embodiment, the  
32 second portion is preferably disposed at or adjacent  
33 the N-terminus of the coat protein. In PVX, the N-  
34 terminus of the coat protein is believed to form a  
35 domain on the outside of the virion.

36

1 The second portion of the chimeric protein may be any  
2 protein, polypeptide or parts thereof, including any  
3 genetically modified versions thereof (such as  
4 deletions, insertions, amino acid replacements and the  
5 like) derived from a source other than the virus from  
6 which the first portion is derived. In certain  
7 embodiments the second portion or the protein derived  
8 therefrom is a biologically active or useful molecule.  
9 The second portion or the protein derived therefrom may  
10 also be a diagnostic reagent, an antibiotic or a  
11 therapeutic or pharmaceutically active agent.  
12 Alternatively the second portion or the protein derived  
13 therefrom may be a food supplement.

14  
15 In an alternative embodiment, the second portion or the  
16 protein derived therefrom may be an indicator protein  
17 chosen for its ability to indicate the location of the  
18 chimeric protein or of the virus particle. Such an  
19 example is the 25kDa jellyfish green fluorescent  
20 protein.

21  
22 The polynucleotide coding for the second (non-viral)  
23 portion may be inserted into an appropriate restriction  
24 site in the viral genome. The restriction site adopted  
25 for such insertion may be naturally occurring in the  
26 viral genome or artificially constructed therein and  
27 the polynucleotide coding for the second portion may be  
28 ligated therein by conventional means. General  
29 techniques for cloning of foreign nucleic acid and  
30 construction of chosen restriction sites is  
31 comprehensively described in the art and is within the  
32 scope of the skilled person.

33  
34 It is preferred that the polynucleotide coding for the  
35 second portion is inserted at or adjacent a terminus of  
36 the polynucleotide coding for the first portion, such

1 that upon translation the chimeric protein has the  
2 first portion at one end and the second portion at the  
3 opposite end. It is not necessary for the first  
4 portion to comprise a whole virus coat protein, but  
5 this remains an option.

6  
7 The virus particle may be formed by the assembly of  
8 chimeric proteins only or by the mixed assembly of  
9 chimeric proteins together with some unmodified or less  
10 modified forms of the naturally occurring wild-type  
11 coat protein which forms the basis of the first  
12 portion. For a mixed virus particle of the latter  
13 type, there must be present polynucleotide(s) encoding  
14 the chimeric protein and the naturally occurring coat  
15 protein. The appropriate protein-coding sequences may  
16 be arranged in tandem on the same molecule. An  
17 alternative would be co-infection (for example of  
18 mutually dependant defective viruses or pseudoviruses)  
19 of two or more viruses or pseudoviruses, or infection  
20 by chimeric virus of a host cell or whole organism  
21 (such as a plant) which expresses such a protein  
22 intrinsically.

23  
24 An advantage is gained by using a virus which forms a  
25 particle with a relatively high pitch of helix. PVX  
26 has a pitch of 3.4nm and is to be preferred over  
27 viruses with a lower pitch. Virus particles with  
28 higher pitches may be able to accommodate larger  
29 protein insertions on their surfaces since their coat  
30 proteins assemble with more space between them than  
31 coat proteins of viruses with lower pitches.

32  
33 A virus or pseudovirus genetically modified to express  
34 the chimeric protein forms a further aspect of the  
35 present invention, as does any host cell infected with  
36 such a virus or pseudovirus.

1 Preferably, the host cell used to replicate the virus  
2 or pseudovirus is a plant cell where the virus is a  
3 plant virus, although insect cells, mammalian cells and  
4 bacteria can be used with viruses which will replicate  
5 in such cells.

6  
7 While modifications and improvements may be  
8 incorporated without departing from the scope of the  
9 invention, embodiments will now be described by way of  
10 the following examples and with reference to the  
11 accompanying drawings in which:

12

13 Fig 1a shows the structure of a gene for a  
14 chimeric protein and of the overcoat vector  
15 pTXS.L2a-CP for use in the present invention;  
16 Fig 1b is a schematic diagram showing the major  
17 features of plasmids useful in the methods of the  
18 present invention;

19 Fig 2 shows a western blot of wild type and  
20 chimeric protein taken from leaves of a plant  
21 infected by a wild-type and a chimeric virus;

22 Fig 3 a, b, c and d show leaves of plants infected  
23 with recombinant virus;

24 Fig 4 a, b, c, d and e are micrographs  
25 illustrating the subcellular distribution of  
26 chimeric protein expressed from chimeric virus  
27 nucleic acid;

28 Fig 5 is an electron micrograph showing  
29 aggregation and immuno-gold labelling of  
30 chimeric viruses;

31 Fig 6 a, b and c are electron micrographs of  
32 negatively-stained chimeric viruses; and

33 Fig 7 is a photograph of a *N benthamiana* leaf  
34 systemically infected with a chimeric virus.

35

36 EXAMPLE 1

1 A general strategy for the production of large  
2 quantities of recombinant proteins is given below using  
3 PVX as an example. A similar strategy could be  
4 employed for other flexuous filamentous or rod-shaped  
5 viruses. A cDNA clone of potato virus X is first  
6 modified to produce fusion proteins between the viral  
7 coat protein and proteins with biological activity or  
8 other commercial applications. The feasibility of this  
9 approach has been demonstrated as described below by  
10 creating a translational fusion between the green  
11 fluorescent protein (25 kDa) of *Aequorea victoria* (1)  
12 and the PVX coat protein (also around 25 kDa).  
13 Functional chimeric viruses have also been made which  
14 are able to express recombinant genes encoding fusions  
15 between the PVX coat protein and the kanamycin  
16 resistance protein Neomycin phosphotransferase (25 kDa).  
17 and between PVX coat protein and the more complex  
18 enzymes  $\beta$ -galactosidase (10-13 kDa) and  $\beta$ -glucuronidase  
19 (68 kDa) respectively.

20  
21 The green fluorescent protein (GFP) from *A. victoria*  
22 (1) is a reporter of gene expression in heterologous  
23 systems (3-6). GFP has an advantage over other marker  
24 proteins in that it can be detected non-invasively,  
25 without any requirement for exogenous substrates or co-  
26 factors (3) since it fluoresces intrinsically without a  
27 requirement for exogenous substrate. In addition,  
28 fluorescence of GFP is retained in fusion proteins  
29 allowing the subcellular localization of fusion  
30 proteins (4).

31  
32 PCR-mutagenesis of a full-length cDNA copy of the  
33 potato virus X genome can be performed to create a  
34 synthetic coding sequence comprising the gene coding  
35 for the protein of interest, the foot and mouth disease  
36 virus 2A protease gene, and the potato virus X coat

1 protein gene. The PVX genome is contained within the  
2 known plasmid pTXS (Fig. 1, reference 25).

3  
4 When reassembled the modified cDNA copy of the viral  
5 genome can be used as a template to synthesize *in vitro*  
6 run-off transcripts. Inoculation of transcripts to  
7 plants can be performed by manual abrasion of  
8 carborundum coated leaves of either *Nicotiana*  
9 *clevelandii* or *N benthamiana*.

10  
11 When the above approach was followed using PVX modified  
12 to express GFP-CP fusion protein, between two and three  
13 days post inoculation the presence of fluorescent  
14 regions in the virus infected plants could be observed  
15 by eye on inoculated leaves by viewing plants under  
16 ultraviolet light. At about ten days post inoculation  
17 GFP-mediated fluorescence was detected in systemic  
18 (non-inoculated) leaf tissue (Figure 7). This  
19 fluorescence was specific to the green fluorescent  
20 protein and was not observed on control plants  
21 inoculated with wild-type PVX.

22  
23 Electron microscopic analysis of viral particles showed  
24 a clear increase in particle width in plants infected  
25 with the GFP-CP containing virus compared with  
26 particles isolated from plants infected with wild-type  
27 PVX (Figure 6).

28  
29 In the strategy used above, foreign proteins were  
30 expressed by fusing them to the amino-terminus of the  
31 PVX coat protein. However other sites may be possible,  
32 eg carboxy-terminus surface loops on some other rod-  
33 shaped or filamentous viruses.

34  
35 Data from previous studies suggest that fusion of the  
36 proteins to the amino terminus of the PVX coat protein

1 is most likely to be successful. Biochemical,  
2 immunological and tritium bombardment data suggest a  
3 model for the structure of the PVX coat protein (10) in  
4 which the N-terminal 33 amino acids form a domain of  $\beta$ -  
5 sheet on the outside of the virion. In contrast, the  
6 C-terminus of the PVX coat protein, which also forms  
7 part of a  $\beta$ -sheet structure, is inaccessible from the  
8 outside of the virion and deletions within it do not  
9 permit the virus to infect plants systemically.

10

11 As an additional optional strategy, the foot and mouth  
12 disease virus (FMDV) 2A protease sequence (12) can be  
13 positioned between the foreign and coat protein  
14 sequences. The FMDV 2A protease is a short (19 amino  
15 acid) peptide which acts *in cis* to cleave the FMDV  
16 polyprotein in a co-translational mechanism. This  
17 protease has been shown to effect the cleavage of  
18 synthetic polyproteins both *in vitro* and *in vivo* (13).  
19 The inclusion of the 2A protease sequence between the  
20 GFP and coat protein can generate a mixed pool of  
21 fusion and cleaved proteins in virus infected cells.  
22 The presence of free coat protein, generated by 2A  
23 protease mediated cleavage, may circumvent this problem  
24 by allowing assembly of virions composed of both free  
25 (ie cleaved) and fused coat protein subunits.

26

27 The formation of virions is an absolute requirement of  
28 PVX for systemic infection of plants (15). The  
29 demonstration herein that GFP-coat protein fusions do  
30 assemble into virions (Fig 7) and spread indicates that  
31 the size of GFP (25kDa) does not interfere with virion  
32 assembly. Fusion proteins which fail to assemble due  
33 to size or other constraints can be produced in  
34 constructs carrying the FMDV 2A protease, or in plants  
35 which are modified to express wild-type coat protein  
36 for the particular virus used. The sequence of the 2A



1 protease peptide can be modified to increase or  
2 decrease the efficiency of co-translational cleavage.

3

4 EXAMPLE 2

5 This example describes a modified form of PVX which  
6 expresses a chimeric gene encoding a fusion between the  
7 *Aequorea victoria* green fluorescent protein and the PVX  
8 coat protein and assembles into virions that are over  
9 twice the diameter of wild-type PVX. The modified  
10 virus moves from cell-to-cell and systemically. The  
11 example demonstrates the potential of fusions between  
12 non-viral protein and virus coat protein for production  
13 of high levels of non-viral proteins in plants.

14

15 The plasmids used in this work were derived essentially  
16 from the plasmid pTXS which contains the PVX genome and  
17 a T7 promoter (described in 25). Fig 1b shows the  
18 following main features of the plasmids: the virus RNA-  
19 dependent RNA polymerase gene (RdRp); virus genes  
20 encoding movement proteins (M1, M2, M3); the virus coat  
21 protein gene (CP); promoters from T7 bacteriophage (T7)  
22 or for the 35S RNA of CaMV (CaMV35S); the  
23 transcriptional terminator of the nopaline synthase  
24 gene of *Agrobacterium tumefaciens* and various  
25 restriction enzyme sites.

26

27 The plasmid pCXA3 was constructed by transfer of the  
28 PVX cDNA from pTXS into the plasmid pB1220.5 between  
29 the CaMV 35SRNA promoter and the nopaline synthase gene  
30 terminator. The plasmid pB1220.5 is similar to the  
31 plasmid pB1221.1 but without the GUS gene (described in  
32 27). The junction between the promoter and the PVX  
33 cDNA was modified by oligonucleotide directed  
34 mutagenesis to the sequence  
35 (5')gatttggagagga\*gaaaactaaacca(3') in which \* denotes  
36 the most 3' non-transcribed position in the promot r

1 sequence and the most 5' transcribed position in the  
2 viral genome (28). Construction of the pVX201 vector  
3 from pCXA3 and pPC2S exploited unique restriction sites  
4 at positions 4945 (Apa1) and 6302 (Xho1) of the PVX  
5 cDNA (25).

6  
7 GFP cDNA was PCR-amplified with primers  
8 (5')gccaatcgatcatgagtaaaggag(3') on the positive strand  
9 and (5')ggaagtcgacacatttatttg(3') from the negative  
10 strand. The bold type represents the initiation and  
11 termination codons of the GFP gene (29). The  
12 underlined type represents Cla1 and Sal1 sites used to  
13 introduce the PCT-amplified sequence into pPVX201 to  
14 generate pPVX204. The plasmid pTXS.GFP was made by  
15 substitution of the region of pPVX204 containing the  
16 GFP sequence into the homologous region of pPC2S.

17  
18 The plasmid pTXS.GFP carries a full-length cDNA copy of  
19 the potato virus X (PVX) genome into which the GFP gene  
20 has been inserted. Inoculation of plants with  
21 transcripts synthesized in vitro from pTXS.GFP results  
22 in the expression of free GFP in infected cells (5).  
23 We prepared a derivative of pTXS.GFP, pTXS.GFP-CP, to  
24 create a translational fusion between the  
25 carboxyterminus of the GFP and the amino-terminus of  
26 the PVX coat protein (CP). pTXS.GFP was used as a  
27 template to produce the GFP-2A-CP fusion gene by  
28 overlap extension PCR using flanking oligonucleotides  
29 complementary to the PVX genome and mutagenic  
30 oligonucleotides to incorporate the 2A protease coding  
31 sequence. Amplified product was subcloned into  
32 pTXS.GFP as a 1.5 kbp fragment using the unique  
33 restriction sites Cla1 and Xho1 to give pTXS.GFP-CP.  
34 Fig. 1a shows a schematic representation of viral cDNAs  
35 used to synthesize infectious run-off transcripts for  
36 the GFP-2A-CP fusion gene. The predicted Mrs of the

1 four viral proteins common to all constructs are.  
2 indicated (K=kD). The polypeptide chain lengths of the  
3 CP, GFP and 2A protease (2A) enclosed by the constructs  
4 are shown. The bars indicate the position of the  
5 subgenomic promoter for the CP. TXS=wild-type PVX;  
6 TXS.GFP=PVX modified to express free GFP from a  
7 duplicated subgenomic promoter; TXS.GFP-CP=PVX modified  
8 to express the GFP-2A-CP fusion protein.

9  
10 Because the GFP and PVX CP are of similar sizes, having  
11 molecular weights of 26.9 kD and 25.1 kD respectively,  
12 it was expected that in a homogenous population of  
13 fusion protein steric effects would prevent virion  
14 formation. Assembly of fusion protein into virions  
15 might be facilitated by the presence of a pool of free  
16 CP. Therefore the GFP and CP nucleotide sequences in  
17 pTXS.GFP-CP were separated by sequence coding for  
18 sixteen amino acids from the foot-and-mouth disease  
19 virus (FMDV) 2A peptide. The 2A region of FMDV  
20 mediates a primary (co-translational) processing event  
21 between the 2A and 2B regions of the FMDV polyprotein  
22 (12) that results in inhibition of peptide bond  
23 formation (13).

24  
25 In vitro run-off transcripts (14), synthesized from  
26 pTXS.GFP and pTXS.GFP-CP (plasmids were linearized with  
27 Spe 1 prior to in vitro transcription reactions as  
28 described in reference 14), were infectious when  
29 inoculated to plants; virus derived from transcript-  
30 infected plants is subsequently referred to as PVX.GFP  
31 and PVX.GFP-CP respectively.

32  
33 Following inoculation of either *Nicotiana clevelandii*  
34 or *N. benthamiana*, both PVX.GFP and PVX.GFP-CP caused  
35 the development of green fluorescent regions which were  
36 first detectable by eye under UV illumination between

1 two and three days post inoculation (Fig. 3A, C).  
2 Subsequent long-distance movement of the virus to  
3 developing leaves led to the appearance of green  
4 fluorescence in systemically infected leaves (Fig. 3B,  
5 D). The rate at which fluorescent regions spread on  
6 inoculated leaves was slower in PVX.GFP-CP infected  
7 plants than PVX.GFP infected plants and the appearance  
8 of fluorescence in systemically infected leaves was  
9 delayed in plants infected with PVX.GFP-CP compared  
10 with PVX.GFP infected plants.

11  
12 Fig. 3 shows leaves of *N. benthamiana* infected with  
13 either PVX.GFP (A, B) or PVX.GFP-CP (C,D). Leaves were  
14 viewed under UV illumination (365 nm) generated from a  
15 Blak Ray B100-AP lamp (Ultra-Violet Products) and  
16 photographed using a Wratten 58 filter to eliminate  
17 chlorophyll auto-fluorescence. The pattern of virus  
18 spread in both cases is similar. A and C identify  
19 inoculated leaves showing the development of  
20 characteristic circular regions. B and D identify  
21 systemically infected leaves showing fluorescence  
22 associated predominantly with the leaf veins. The  
23 developing leaf (D) was undergoing the sink-source  
24 transition (20) resulting in lack of virus movement  
25 into the apical portion of the leaf.

26  
27 Fig 4a is a confocal fluorescence image of a  
28 systemically infected leaf in transverse section  
29 showing the location of PVX.GFP-CP containing  
30 viroplasms within individual cells of the leaf. 4b is  
31 a bright field image of section shown in (A) showing  
32 the typical arrangement of epidermis (E), palisade (P)  
33 and mesophyll(M) cells. A vascular bundle (B) is also  
34 present (scale=50  $\mu$ m). 4c is a confocal image of  
35 palisade cells from a leaf systemically infected with  
36 PVX.GFP-CP showing the GFP-containing viroplasms (V)

1 assembled into cage-like structures (scale=5  $\mu$ m). 4d  
2 shows a leaf trichome systemically infected with  
3 PVX.GFP, in which the GFP is associated with the  
4 nucleus (N) and the cytoplasm. 4e shows a leaf  
5 trichome systemically infected with PVX.GFP-CP, in  
6 which the GFP is predominantly targeted to viroplasms  
7 (V) within individual trichome cells (scale=10  $\mu$ m).

8  
9 In systemically infected (ie non-inoculated) leaves  
10 both PVX.GFP and PVX.GFP-CP moved from the phloem into  
11 surrounding bundle sheath and mesophyll cells and  
12 eventually into the epidermis (Fig. 4A, B). Under the  
13 confocal microscope transverse sections of the  
14 systemically infected leaves showed that in PVX.GFP-CP  
15 infected cells green fluorescence was detected  
16 predominantly in viroplasms, cytoplasmic structures  
17 comprising aggregated viral particles that often  
18 appeared as continuous cage-like structures within the  
19 cell (Fig 4C, 5). By contrast, in PVX.GFP infected  
20 cells, the green fluorescence was associated with  
21 nuclei and showed a relatively uniform distribution  
22 throughout the cytoplasm. This difference in the  
23 subcellular distribution of the GFP was seen clearly in  
24 leaf trichome cells (Fig. 4D, E).

25  
26 The distribution of fluorescence suggested that the  
27 majority of GFP produced in PVC.GFP-CP infected plants  
28 was still fused to the CP and that these fusion  
29 proteins were assembling into virions, which  
30 subsequently formed viroplasms.

31  
32 Western blotting of protein extracts from inoculated *N.*  
33 *clevelandii* leaves, probed with CP specific antiserum  
34 (16), showed that most of the immunoreactive protein in  
35 PVX.GFP-CP infected plants comprised the fusion  
36 protein. Protein extracts were prepared by grinding

1 leaf tissue in two volumes (w/v) protein extraction  
2 buffer (15). An equal volume of 2x SDS load buffer was  
3 added and the extracts were boiled for two minutes.  
4 Proteins were electrophoresed, blotted to  
5 nitrocellulose and probed with rabbit polyclonal anti-  
6 PVX CP antiserum as described previously (16). Fig 2  
7 illustrates the data obtained. Protein was prepared  
8 from mock inoculated control plants (lane 2), or from  
9 plants inoculated with in vitro transcripts synthesized  
10 from plasmid DNAs (TXS=lane 1; TXS.GFP-CP=lane 3;  
11 TXS.GFP=lane 4). Mrs of native CP, the GFP-2A-CP  
12 fusion protein and CP released by 2A protease mediated  
13 cleavage are 25.1, 53.2 and 24.8 kD respectively. The  
14 Mrs of standards are shown to the left of Fig 2 in kD.

15

16 The low level of smaller immunoreactive protein  
17 detected in PVX.GFP-CP infected tissue is assumed to  
18 result from processing of the fusion protein mediated  
19 by the FMDV 2A peptide rather than from contamination  
20 with virus deletion mutants as similar ratios of fusion  
21 to free protein were observed in all other samples  
22 analyzed and RT-PCR analysis of the same samples used  
23 for protein analysis showed no evidence of deleted  
24 forms of the viral genome (17). In addition when blots  
25 were probed with GFP specific antiserum the ratio of  
26 free protein to fusion protein was the same as that  
27 observed using anti-CP antiserum (17).

28

29 In order to determine the subcellular location of the  
30 viral CP ultrathin sections of inoculated leaves were  
31 prepared for immuno-gold labelling, using a polyclonal  
32 antibody to the PVX CP. Leaf tissues were fixed and  
33 embedded in Araldite (TM) resin for immuno-gold  
34 labelling as described previously (17). Ultrathin  
35 sections on nickel grids were labelled using polyclonal  
36 rabbit antiserum to the PVX CP followed by goat anti-

1 rabbit gold conjugate (GAR-15 nm, Amersham  
2 International). Aggregation of the filamentous  
3 virions into viroplasms is marked with arrows in Fig 5.  
4 Dense gold labelling was predominantly associated with  
5 the viroplasms in both PVX.GFP and PVX.GFP-CP infected  
6 cells. The pattern of virus aggregation seen in the  
7 electron microscope for both PVX.GFP-CP (Fig. 5) and  
8 PVX.GFP was remarkably similar to the cages of  
9 viroplasm seen with PVX.GFP-CP under the confocal  
10 microscope (Fig. 4c).

11  
12 For negative staining, virus particles were trapped  
13 from virus infected sap extracts by immuno-sorbent  
14 electron microscopy (18) using anti-PVX CP antiserum,  
15 and stained with 2% sodium phosphotungstate (pH 7).  
16 Analysis of negatively stained virus samples under the  
17 electron microscope revealed that PVX.GFP-CP virions  
18 were decorated along their length with globular  
19 extensions (Fig. 6a,b). Fig 6c shows negatively  
20 stained virus rods isolated from PVX.GFP infected  
21 plants (scale=50 nm). Differences in virion diameter  
22 are seen most clearly where virions are aligned in  
23 parallel (a and c, large darts). In Fig 6b small  
24 globular extensions (small darts) are apparent along  
25 the length of the PVX.GFP-CP virus (scale=25 nm). The  
26 PVX.GFP-CP virions had a mean diameter of 29.7 nm, more  
27 than twice the diameter of PVX.GFP virions (12.6 nm;  
28 Fig. 6c).

29  
30 A modified form of PVX.GFP-CP, in which the FMDV 2A  
31 peptide sequence carries three amino acid  
32 substitutions, introduced to prevent processing of the  
33 polyprotein, was unable to move from cell-to-cell and  
34 did not give rise to fluorescent viroplasms.  
35 Infections with this mutant were restricted to single  
36 epidermal cells and fluorescence was detected uniformly

1 throughout the cytoplasm and in association with  
2 nuclei, as observed for PVX.GFP infections (17),  
3 suggesting that the presence of free CP is essential  
4 for either initiation of elongation of virions.

5  
6 The fluorescence generated by the GFP attached to  
7 virions was intense, allowing rapid detection of viral  
8 aggregates within individual living cells.  
9 Furthermore, confocal microscopy allowed the  
10 noninvasive imaging of the pathway of cell-to-cell  
11 movement of virus-GFP constructs, pinpointing the  
12 specific cell types in which virus accumulated. For  
13 confocal imaging leaves were excised from the plant and  
14 sectioned transversely into 200  $\mu$ m slices using a  
15 vibrotome. The sections were immediately mounted in  
16 water and viewed under a Bio-Rad MRC 1000 confocal  
17 laser scanning microscope at an excitation wavelength  
18 of 488 nm using a krypton-argon laser.

19  
20 Previous descriptions of assembly competent plant RNA  
21 viruses carrying CP extensions have involved small  
22 oligopeptide fusions (19). The data presented in this  
23 example suggest that the system described could be used  
24 for the production of proteins that are at least as  
25 large as the viral CP of PVX.

26  
27 The strategy described to generate GFP-coat protein  
28 fusions can be easily applied to proteins other than  
29 GFP. We modified the plasmid pTXS.GFP-CP which carries  
30 the GFP-2A-CP fusion protein gene to enable the facile  
31 insertion of novel coding sequence as a fusion to the  
32 2A-CP cassette. This modified plasmid, pTXS.L2a-CP  
33 shown in Fig. 1a (deposited under No NCTC 12918 at the  
34 National Collection of Type Cultures at 61 Colindale  
35 Avenue, London NW9 5HT on 18 October 1995) carries a  
36 series of unique restriction enzyme recognition sites



1 (Cla1, Ega1, Sma1, Ehe1) or polylinker that replaces  
 2 the GFP coding sequence of pTXS.GFP-CP. By digesting  
 3 the vector pTXS.L2a-CP at one or more of the polylinker  
 4 restriction enzyme sites it is possible to insert the  
 5 coding sequence for any given protein such that a  
 6 fusion protein gene is created comprising the novel  
 7 gene, the FMDV 2A peptide and the PVX coat protein as a  
 8 translational fusion.

9  
 10 The plasmid vector pTXS.L2a-CP was prepared by PCT-  
 11 based mutagenesis of the plasmid pTXS.GFP-CP using  
 12 standard techniques (26). The oligonucleotide 2aL5'  
 13 was annealed to the primer 2aL3' and extended with T4  
 14 DNA polymerase.

15  
 16 The sequence of primers used was

17  
 18 2aL5': 5' TCG GCC GTC CCG GGG GCG 3'  
 19 ||| ||| ||| ||| ||| |||  
 20 2aL3': 3' AGC CGG CAG GGC CCC CGC GGT TAA AAC TGG AAG  
 21  
 22 AAT TCG AAA 5'

23  
 24 The extended product was gel purified and cloned into  
 25 the plasmid M13RK8.2 (30). An Eag 1/ Afl 11 fragment  
 26 was excised from the resulting plasmid and cloned  
 27 between the same sites of the plasmid pTXS.GFP-CP in  
 28 place of the GFP gene.

29  
 30 Thus, the nucleotide sequence of the new linker in  
 31 pTXS.L2a-CP is

32 Cla1 Eag1 Sma1 Ehe1

33  
 34 /\_\_\_\_\ /\_\_\_\_\ /\_\_\_\_\ /\_\_\_\_\

35 Nts: AT CGA TCC GGC CGT CCC GGG GGC GCC AAT TTT

36 Amino acids: Pro Gly Gly Ala Asn Phe

1 Insertion of foreign genes into the pTXS.P-CP  
2 polylinker are most easily performed by PCR  
3 amplification of the foreign gene using  
4 oligonucleotides designed to incorporate appropriate  
5 restriction enzyme recognition sites at the 5'- and 3'-  
6 termini of the foreign coding sequence such that the  
7 gene for the synthetic polyprotein comprises a single  
8 open reading frame. We have demonstrated the utility  
9 of this approach using the gene encoding neomycin  
10 phosphotransferase (NPT) which confers resistance to  
11 the antibiotic kanamycin and is present in most  
12 commercially available plasmids as a selection tool.  
13 The 0.73 kb (NPT) coding sequence was inserted into the  
14 polylinker of pTXS.P-CP to give the plasmid pTXS.NPT-  
15 CP. Transcripts synthesized in vitro from the  
16 pTXS.NPT-CP template were infectious on plants and the  
17 virus moved both locally and systemically. Assembly of  
18 PVX.NPT-CP virions results in "overcoat" virus  
19 particles carrying the NPT protein on the surface of  
20 the virions.

21  
22 The advantages of the invention are as follows:

23  
24 (i) Standard purification procedures exist (eg  
25 polyethylene glycol precipitation and centrifugation)  
26 for these highly stable virus particles to remove plant  
27 proteins and cellular debris and to give an extremely  
28 pure suspension of plant virus particles. Plant  
29 viruses are innocuous to humans, ingestion experiments  
30 have already revealed that they pass straight through  
31 the intestine undamaged.

32  
33 (ii) By attaching the foreign protein to each (or a  
34 subset of) coat protein subunits optionally with a  
35 suitable cleavage-sensitive linker sequence will allow,  
36 following virus purification from the infected plant

1 sap, foreign protein to be released into free solution  
2 simply by incubation with the appropriate proteolytic  
3 enzyme. The released virus particles remain stable and  
4 of high molecular weight so that they can be separated  
5 from the short peptide either by simple dialysis  
6 procedures (continuous flow type), or by differential  
7 centrifugation or selective precipitation.

8  
9 (iii) Yields of cleaved foreign protein from such a  
10 system could reach 50% or more of the total weight of  
11 virus recovered. Each helical virus particle has 95%  
12 of its weight as coat protein, and each coat protein  
13 subunit has a molecular weight of approximately 25 kD.  
14 In the model system already developed the green  
15 fluorescent protein also has a molecular mass of  
16 approximately 25 kD. Yields of potato virus X can be  
17 extremely high (up to 5 gm/kg wet weight of infected  
18 leaf after several weeks).

19  
20 (iv) The flexibility of scale that can be achieved in  
21 plants is also attractive in terms of reducing the cost  
22 of protein production and avoids the need for high  
23 level capital investment such as in animal or microbial  
24 cell culture facilities.

25  
26 (v) The use of set-aside land and/or discredited crops  
27 such as tobacco for the alternative production of  
28 highly prized, pharmaceutically active proteins would  
29 lead to considerable added value in the peri-  
30 agricultural sector.

31

1     REFERENCES

2

3     The following documents referred to in the text are  
4     incorporated herein by reference:

5

6     1. B.L. Epel, Plant Mol. Biol. 26, 1343-1356 (1994):  
7     W.J. Lucan & R.L. Filbertson, Annu. Rev. Phytopathol.  
8     32, 387-411 (1994); B.G. McLean, W. Waigmann, V.  
9     Citovsky & P. Zambryski, trends Microbiol. 1, 105-109  
10    (1993).

11

12    2. D. C. Prasher, V.K. Eckenrode, W.W. Ward, F.G.  
13    Prendergast & M.J. Cormier, Gene 111, 229-233 (1992).

14

15    3. M Chalfie, Y. Tu, G. Euskirchen, W.W. Ward & D.C.  
16    Prasher, Science 263, 802-805 (1994).

17

18    4. S. Wang & T. Hazelrigg, Nature 369, 400-403 (1994).

19

20    5. D.C. Baulcombe, S. Chapman & S. Santa Cruz, Plant  
21    J. 7, 1045-1053 (1995).

22

23    6. R.P. Niedz, M.R. Sussman & J.S. Satterlee, Plant  
24    Cell Rep. 14, 403-406 (1995).

25

26    7. S. Chapman, T. Kavanagh & D.C. Baulcombe, Plant J.  
27    2, 549-557 (1992).

28

29    8. H.B. Scholthof, T.J. Morris & A.O. Jackson, Mol.  
30    Plant-Microbe Interact. 6, 309-322 (1993).

31

32    10. L.A Baratova et al., Virology 188, 175-180 (1992).

33

34    11. R. Koenig & L. Torrance, J. Gen. Virol 67, 2145-  
35    2151 (1986).

36

- 1     12. M.D. Ryan, A.M.Q. King & G.P. Thomas, J. Gen.  
2     Virol. 72, 2727-2732 (1991).  
3
- 4     13. M.D. Ryan and J. Drew, EMBO J. 13, 928-933 (1994).  
5
- 6     14. T. Kavanagh et al., Virology 189, 609-617 (1992).  
7
- 8     15. S. Chapman, G. Hills, J. Watts & D.C. Baulcombe,  
9     Virology 191, 223-230 (1992).  
10
- 11    16. C. Davies, G. Hills & D.C. Baulcombe, virology  
12    197, 166-175 (1993).  
13
- 14    17. C. Fasseas, I.M. Roberts & A.F. Murant, J. Gen.  
15    Virol. 70, 2741-2749 (1989).  
16
- 17    18. I.M. Roberts, in Electron microscopy of proteins:  
18    5. Viral structure, J.R. Harris & R.W. Horne, Eds.  
19    (Academic Press, New York, 1986), pp 293-357.  
20
- 21    19. H Hamamoto et al., BIO/TECHNOLOGY 11, 930-932  
22    (1993); R. Usha et al., Virology 197, 366-374 (1993);  
23    C. Porta et al., Virology 202, 949-955 (1994); T.H.  
24    Turpen et al., BIO/TECHNOLOGY 13, 53-57 (1995).  
25
- 26    20. R. Turgeon, Annu. Rev. Plant Physiol. Plant Mol.  
27    Biol. 40, 119-138 (1989).  
28
- 29    21. Abouhaidar, M.G. and Lai, R. (1989) J. Gen. Virol.  
30    70, 1871-1875.  
31
- 32    22. Kokyakov, V.N. Harwig, S.S.L., Panyutich, E.A.,  
33    Shevchenko, G.M.A., Shamova, O.V., Korneva, H.A. and  
34    Lehrer, R.I. (1993) FEBS letters 327, #2, 231-236.  
35
- 36    23. Pardi, A., Zhang, X-L., Selsted, M.E., Skalicky,

- 1 J.J. and Yip, P.F. (1992) Biochemistry 31, 11357-11364.
- 2
- 3 24. Lehrer, R.J., Ganz, T. and Selsted, M.E.
- 4 Defensins: Endogenous Antibiotic Peptides of Animal
- 5 Cells. (1991) Cell 64 229-230.
- 6
- 7 25. Kavanagh, T Goulden, M Santa Cruz, S., Chapman,
- 8 S., Barker, I and Baulcombe, D.C. (1992) Virology,
- 9 189, 609-617.
- 10
- 11 26. Sambrook et al (1989. Molecular cloning, a
- 12 laboratory manual. Cold Spring Harbour Laboratory.
- 13
- 14 27. Jefferson et al (1987) Plant Vol. Biol. Rep. 5,
- 15 387-405.
- 16
- 17 28. Guilley et al (1982) Cell 30, 763-773.
- 18
- 19 29. Prasher et al (1992) Gene 111, 229-233.
- 20
- 21 30. Waye et al (1985) Nucleic Acids Res. 13(23) 8561-
- 22 8571.
- 23

## 1 Claims:

2

3 1 A method of producing a chimeric protein, the  
4 method comprising:

5

6 a providing a rod-shaped recombinant virus or  
7 pseudovirus containing a polynucleotide encoding a  
8 chimeric protein having a first (viral) portion  
9 and a second (non-viral) portion, the chimeric  
10 protein being capable of assembly into a virus  
11 particle such that the second portion is disposed  
12 on the exterior surface of the assembled virus  
13 particle;

14

15 b infecting a host cell with the virus or  
16 pseudovirus; and

17

18 c allowing replication of the virus or pseudovirus  
19 and expression of the chimeric protein in the host  
20 cell.

21

22 2 A method according to claim 1, wherein the  
23 chimeric protein assembles into a virus particle.

24

25 3 A method according to claim 1 or claim 2, wherein  
26 the virus or pseudovirus is subsequently purified from  
27 the host cell.

28

29 4 A method according to claim 2 or claim 3,  
30 including the step of cleaving the second portion or a  
31 protein derived therefrom from the first portion after  
32 purification of the virus or pseudovirus from the host  
33 cell.

34

35 5 A method according to any preceding claim, wherein

36

1 a linker peptide is incorporated between the first and  
2 second portions.

3

4 6 A method according to any preceding claim, wherein  
5 a proteolytic cleavage site is incorporated on one of  
6 or between the first and second portions.

7

8 7 A method according to claim 1, wherein the first  
9 and second portions are separated from one another  
10 before or during assembly of the virus particle, such  
11 that the host cell contains free protein derived from  
12 the second portion.

13

14 8 A method according to any preceding claim, wherein  
15 protein derived from the second portion is purified  
16 from the host cell after replication.

17

18 9 A method according to any preceding claim, wherein  
19 the virus or pseudovirus is derived from a plant virus.

20

21 10 A method according to any preceding claim, wherein  
22 the virus or pseudovirus is derived from potato virus  
23 X.

24

25 11 A method according to any preceding claim, wherein  
26 the second portion is disposed at or adjacent the N-  
27 terminus of the viral coat protein.

28

29 12 A method according to any preceding claim, wherein  
30 the second portion is a diagnostic reagent, an  
31 antibiotic, a therapeutic or pharmaceutically active  
32 agent, a vaccine or a food supplement.

33

34 13 A method according to any preceding claim, wherein  
35 the virus or pseudovirus particle comprises a mixture  
36 of chimeric protein and wild-type coat protein.



1     14     A method according to any preceding claim, wherein  
2     the virus or pseudovirus particle has a relatively high  
3     pitch of helix.  
4

5     15     A method according to claim 12, wherein the pitch  
6     of the helix is more than 2nm.  
7

8     16     A method according to any preceding claim, wherein  
9     the virus or pseudovirus is flexuous.  
10

11    17     A method according to any preceding claim, wherein  
12    the host cell is infected with virus or pseudovirus in  
13    particle form.  
14

15    18     A method according to any one of claims 1-16,  
16    wherein the host cell is infected with virus or  
17    pseudovirus in nucleic acid form.  
18

19    19     A method according to any preceding claim, wherein  
20    the second portion or a peptide derived therefrom has a  
21    molecular weight in excess of 10 kDa.  
22

23    20     A virus or pseudovirus genetically modified to  
24    express a chimeric protein, the chimeric protein having  
25    a first (viral) portion linked to a second (non-viral)  
26    portion, the chimeric protein being capable of self-  
27    assembly into a virus particle so that the second  
28    portion is disposed on the exterior surface of the  
29    assembled virus particle.  
30

31    21     A host cell, plant, animal or insect infected  
32    with a virus or pseudovirus according to claim 20.  
33

34    22     A polynucleotide capable of producing a virus or  
35    pseudovirus according to claim 20.  
36

1     23     A chimeric protein produced by a method according  
2     to any one of claims 1-19.

3

4     24     The plasmid pTXS.L2a-CP as deposited under No NCTC  
5     12918 on 18 October 1995 at the National Collection of  
6     Type Cultures.

7

8

9

FIGURE 1a

1/7





FIGURE 1b

2/7



3/7

FIGURE 2




FIGURE 3




FIGURE 4





FIGURE 5




FIGURE 6





7/7

FIGURE 7



# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB 95/02457

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/62 C12N15/83 C07K14/08 C07K14/435 C12N7/01  
C12N5/10

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,91 15587 (COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION) 17 October 1991 see page 7, line 8 - line 22; example 4 see page 3, line 18 - page 4, line 27 --- -/--	1-3,8,9, 12,18, 20-23



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

26 January 1996

Date of mailing of the international search report

15.03.1996

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+ 31-70) 340-3016

Authorized officer

Montero Lopez, B

# INTERNATIONAL SEARCH REPORT

International Publication No  
PCT/GB 95/02457

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>BIOTECHNOLOGY, vol. 11, no. 10, October 1993 NEW YORK US, pages 1166-1170, MITTUR N. JAGADISH ET AL. 'High level production of hybrid Potyvirus-like particles carrying repetitive copies of foreign antigens in Escherichia coli' see abstract see page 1166, left column, paragraph 3 - page 1167, right column, paragraph 1 see page 1167, right column, paragraph 4 - page 1169, left column, paragraph 3 ---</p>	<p>1-3, 9-13, 20-23</p>
X	<p>WO,A,93 03161 (DONSON, JON ET AL.) 18 February 1993 see page 5, paragraph 2 see page 6, paragraph 3 - page 7, paragraph 3 see page 15, paragraph 2 - page 17, paragraph 2 see page 20, paragraph 3 - page 21, paragraph 1 see page 23, paragraph 2 - page 24, paragraph 1 see page 26, paragraph 5 - page 27, paragraph 3 see page 29, paragraph 2 - page 30, paragraph 1 see page 33, paragraph 2 - page 34, paragraph 1; examples 8,12 ---</p>	<p>1-24</p>
X	<p>DATABASE WPI Section Ch, Week 9013 Derwent Publications Ltd., London, GB; Class B04, AN 90-096520 'New plant virus RNA vector obtained by connecting foreign gene downstream of coat protein gene of tobamo virus RNA' &amp; JP,A,02 049 591 (SUMITOMO CHEM IND KK) , 19 February 1990 see abstract ---</p>	<p>1,3,8,9, 11,20-23</p>
X	<p>WO,A,92 18618 (AGRICULTURAL GENETICS COMPANY LIMITED) 29 October 1992 cited in the application</p>	<p>20-23</p>
A	<p>see page 2, paragraph 2 - page 3, paragraph 1 see page 3, paragraph 3 - page 4, paragraph 1 see page 4, paragraph 3 - page 5, paragraph 3 see page 17, paragraph 2 - page 18, paragraph 5 ---</p>	<p>1-19,24</p>
	-/--	

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB 95/02457

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	VIROLOGY, vol. 197, no. 1, November 1993 ORLANDO US, pages 366-374, RAMAKRISHNAN USHA ET AL. 'Expression of an animal virus antigenic site on the surface of a plant virus particle'	20-23
A	see abstract see page 366, left column, paragraph 1 - right column, paragraph 1 see page 368, left column, last paragraph - right column, paragraph 2 see page 370, right column, paragraph 1 - page 372, right column, paragraph 1 ---	1,2,9, 11-13,18
P,X	VACCINE, vol. 13, no. 12, August 1995 GUILDFORD GB, pages 1051-1057, JOHN FITCHEN ET AL. 'Plant virus expressing hybrid coat protein with added murine epitope elicits autoantibody response' see abstract see page 1051, right column, paragraph 2 - page 1052, left column, paragraph 1 see page 1053, right column, paragraph 1 - page 1054, right column, paragraph 2 see page 1055, left column, paragraph 1 - page 1056, right column, paragraph 1 -----	1-3,8,9, 11,12, 20-23

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/GB 95/02457

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9115587	17-10-91	AU-B- 7667591 EP-A- 0527767	30-10-91 24-02-93
WO-A-9303161	18-02-93	US-A- 5316931 AU-B- 3351193 CA-A- 2114636 EP-A- 0596979 JP-T- 7503361	31-05-94 02-03-93 18-02-93 18-05-94 13-04-95
WO-A-9218618	29-10-92	AU-B- 661479 AU-B- 1447992 EP-A- 0580635 HU-A- 65554 JP-T- 6506583	27-07-95 17-11-92 02-02-94 28-06-94 28-07-94